LIPO GANTRISIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPO GANTRISIN (LIPO GANTRISIN).
Lipo Gantrisin is a liposomal formulation of sulfisoxazole, a sulfonamide antibiotic. It inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby bacterial DNA replication.
| Metabolism | Primarily metabolized via acetylation and glucuronidation in the liver; undergoes enterohepatic recirculation. |
| Excretion | Lipo Gantrisin is excreted primarily renally (70-80%) as unchanged drug and its acetylated metabolite. Biliary/fecal elimination accounts for 20-30%, with enterohepatic recirculation present. |
| Half-life | The terminal elimination half-life is approximately 7-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min). This necessitates dose adjustment in renal disease. |
| Protein binding | Approximately 60-70% bound to plasma albumin. |
| Volume of Distribution | Apparent volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily into extracellular fluid. It does not significantly penetrate the CNS or prostate. |
| Bioavailability | Oral bioavailability is 85-95% after tablet administration. Suspension has slightly lower bioavailability (80-90%) due to food effects. |
| Onset of Action | Peak serum concentrations occur within 2-4 hours after oral administration; bacteriostatic effect begins within 12-24 hours after achieving therapeutic levels. For intravenous administration, onset is immediate with therapeutic levels reached within 30 minutes. |
| Duration of Action | The bacteriostatic effect persists for 12-24 hours, supporting twice-daily dosing. Clinical improvement in urinary tract infections is typically seen within 48-72 hours. |
| Molecular Weight | 267.31 |
2-4 mL (80-160 mg sulfisoxazole equivalent) intramuscularly every 12 hours for 5-7 days.
| Dosage form | EMULSION |
| Renal impairment | CrCl 30-60 mL/min: administer every 18-24 hours; CrCl 15-29 mL/min: administer every 24-48 hours; CrCl <15 mL/min or dialysis: administer every 48-72 hours. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25%; Child-Pugh class C: reduce dose by 50%. |
| Pediatric use | Infants and children: 50-75 mg/kg of sulfisoxazole equivalent intramuscularly every 12 hours; maximum 6 mL per dose. |
| Geriatric use | Reduce dose by 25-50% due to age-related decline in renal function; monitor renal function and serum levels. |
| 1st trimester | Contraindicated due to risk of teratogenicity (folate antagonism). Avoid use. |
| 2nd trimester | Contraindicated due to potential for fetal harm (e.g., kernicterus). Avoid use. |
| 3rd trimester | Contraindicated due to risk of neonatal hemolysis and kernicterus. Avoid use. |
Clinical note
Comprehensive clinical and safety monograph for LIPO GANTRISIN (LIPO GANTRISIN).
| Placental transfer | Crosses placenta readily; achieves fetal serum concentrations 50-80% of maternal levels. |
| Breastfeeding | Excreted in breast milk; may cause hemolytic anemia in G6PD-deficient infants and kernicterus in jaundiced neonates. Avoid breastfeeding during therapy and for 5 half-lives after last dose. |
| Lactation Rating |
■ FDA Black Box Warning
Sulfonamides, including sulfisoxazole, have been associated with fatal reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Hypersensitivity reactions may occur even with prior use.
| Serious Effects |
Hypersensitivity to sulfonamidesPregnancy at termBreastfeedingSevere hepatic or renal impairmentPorphyriaG6PD deficiency
| Precautions | Monitor for severe hypersensitivity reactions (e.g., Stevens-Johnson syndrome). Use caution in patients with renal impairment (dose adjustment required), hepatic impairment, G6PD deficiency (risk of hemolytic anemia), and porphyria. Avoid use in infants <2 months due to risk of kernicterus. Maintain adequate hydration to prevent crystalluria. |
| Food/Dietary | Food does not significantly affect absorption. Avoid alcohol as it may increase side effects. Ensure adequate fluid intake to prevent crystalluria; do not restrict fluids. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category C. In animals, sulfonamides cause cleft palate and other fetal malformations at high doses. Human data limited: first trimester use associated with small increased risk of neural tube defects; third trimester use contraindicated due to risk of kernicterus in newborn. Avoid in pregnancy near term. |
| Fetal Monitoring | Monitor maternal CBC, urinalysis, renal function, and hepatic function periodically. Monitor fetus via ultrasound for potential growth restriction or anomalies if exposure in first trimester. Newborn assessment for jaundice and kernicterus signs if used near term. |
| Fertility Effects | No specific data on fertility impairment in humans. Animal studies have not shown adverse effects on fertility at clinically relevant doses. |
| Clinical Pearls | Lipo Gantrisin is a liposomal formulation of sulfisoxazole, indicated for urinary tract infections. Monitor renal function and obtain baseline urinalysis; adjust dose in renal impairment. Maintain adequate hydration to prevent crystalluria. Avoid use in patients with sulfonamide allergy, porphyria, or G6PD deficiency. |
| Patient Advice | Take exactly as prescribed; do not skip doses. · Complete the full course even if symptoms improve. · Drink plenty of fluids to prevent kidney stones. · Avoid prolonged sun exposure; use sunscreen. · Report rash, fever, sore throat, or unusual bleeding. · Inform doctor if pregnant, breastfeeding, or planning pregnancy. |